InsidersTradesSigma
Hikma Pharmaceuticals PLC: directors' dealings · United Kingdom · RNS (LSE)
Explore the full management transaction log of Hikma Pharmaceuticals PLC, a listed issuer based in United Kingdom. Shares are listed on UK GB, under the supervision of RNS (LSE). The latest transaction was disclosed on 5 June 2026 (Purchase). Among the most active insiders: Mazen Darwazah. Every trade is free.
119
Insider Decl.
0
Thresholds
€15m
54 ops.
Buy Volume
€2m
7 ops.
Sell Volume
22Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 5 June 2026
Declarations119 total
0London Stock Exchange (XLON)RNS:9597628-1
Ideal exit: 26 Feb 2027 (T+270)
0London Stock Exchange (XLON)RNS:9597628-2
Ideal exit: 26 Feb 2027 (T+270)
0London Stock Exchange (XLON)RNS:9597628-0
Ideal exit: 26 Feb 2027 (T+270)
0London Stock Exchange (XLON)RNS:9597628-3
Ideal exit: 26 Feb 2027 (T+270)
0London Stock Exchange (XLON)RNS:9597628-4
Ideal exit: 26 Feb 2027 (T+270)
38,222 shares@ £14.4920.1% of flowLondon Stock Exchange (XLON)RNS:9597628-5
73,859 sharesLondon Stock Exchange (XLON)RNS:d44dbdfb-743e-4c57-a372-497ad09925dd-2
Ideal exit: 26 Feb 2027 (T+270)
73,622 sharesLondon Stock Exchange (XLON)RNS:d44dbdfb-743e-4c57-a372-497ad09925dd-3
Ideal exit: 26 Feb 2027 (T+270)
41,037 sharesLondon Stock Exchange (XLON)RNS:d44dbdfb-743e-4c57-a372-497ad09925dd-4
Ideal exit: 26 Feb 2027 (T+270)
111,573 sharesLondon Stock Exchange (XLON)RNS:d44dbdfb-743e-4c57-a372-497ad09925dd-0
Ideal exit: 26 Feb 2027 (T+270)
76,444 shares@ £14.4920.1% of flowLondon Stock Exchange (XLON)RNS:d44dbdfb-743e-4c57-a372-497ad09925dd-5
93,413 sharesLondon Stock Exchange (XLON)RNS:d44dbdfb-743e-4c57-a372-497ad09925dd-1
Ideal exit: 26 Feb 2027 (T+270)
407 shares@ £14.0986.3% of flowLondon Stock Exchange (XLON)RNS:549f9a76-e199-4690-8f52-59ddfd93c657-0
Ideal exit: 30 Jan 2027 (T+270)
2,337 shares@ £14.0981.2% of flowLondon Stock Exchange (XLON)RNS:549f9a76-e199-4690-8f52-59ddfd93c657-1
Ideal exit: 30 Jan 2027 (T+270)
178 shares@ £14.0981.8% of flowLondon Stock Exchange (XLON)RNS:549f9a76-e199-4690-8f52-59ddfd93c657-2
Ideal exit: 30 Jan 2027 (T+270)
14,455 shares@ £13.7666.7% of flowLondon Stock Exchange (XLON)RNS:7e577389-dfc6-4254-b481-e9f10701b63b
Ideal exit: 22 Jan 2027 (T+270)
11,309 shares@ £13.0928.8% of flowLondon Stock Exchange (XLON)RNS:20a6a8b1-a14c-4475-9249-b33a586e281e-0
59,221 sharesOutside a trading venueRNS:8692df49-f37d-43c7-8ebe-66aeba9a2ed8-3
88,860 sharesOutside a trading venueRNS:8692df49-f37d-43c7-8ebe-66aeba9a2ed8-4
49,502 sharesOutside a trading venueRNS:8692df49-f37d-43c7-8ebe-66aeba9a2ed8-5
40,043 sharesOutside a trading venueRNS:8692df49-f37d-43c7-8ebe-66aeba9a2ed8-6
87,317 sharesOutside a trading venueRNS:8692df49-f37d-43c7-8ebe-66aeba9a2ed8-7
186,485 sharesOutside a trading venueRNS:8692df49-f37d-43c7-8ebe-66aeba9a2ed8-0
25 of 119 declarations